Updated 12:02 GMT, 20 Nov 2026 SPX 7,175.83 -2.02% NDX 26,517.05 -2.21% VIX 29.84 +4.92% GOLD 3,583.60 -2.76% CL 82.29 -1.11% BTC 61,702.52 -0.32%
NAS100 26,517 −2.21% S&P 7,176 −2.02% GOLD $3,584 −2.76% BTC $61,703 −0.32% VIX 29.84 +4.92% latest tape · as of 12:02 UTC
The Screen · Healthcare · Drug Manufacturers - General

AstraZeneca PLC logoAstraZeneca PLC

AZN · NASDAQ (ADR) · Market cap $260.7B · 96,100 employees

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines.

Not yet scored
175.41

Price as of 19 Nov 2026Daily close, not a live quote

Screened 2026-11-19 · the tape above runs as of 12:02 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed

Key facts today

  • Price175.41 at the 19 Nov 2026 close
  • Our value readFair vs our fair value, as of 19 Nov 2026
  • Our regime readMarkup, as of 15 Nov 2026
  • Ethical screenNot yet scored
  • OptionsOpen interest leans heavily to calls (put/call 0.59)
  • Last reviewed19 Nov 2026 (1 day ago)
  • Release timesRelease and earnings times on your chart: Event Guard Mentor

A summary of the dated readings below, not a live quote and not advice.

PRICE · ONE YEAR

Our fair-value range: 161.69 to 185.94 , base estimate 161.69 (screen dated 2026-11-19).

Current read
Markup ?
Fair · screened 2026-11-19
  • Trend Markup
  • Insiders no filings inside 60 days, left as found
  • Positioning no disclosures inside 60 days, left as found
  • Options put/call open interest 0.59, read 2026-11-19
  • Ethical screen not yet scored
Price175.41
Fair value161.69
Ethical score50.0/100
Value readFairas of 19 Nov 2026
Our investment reviews on this name
2026-11-01Read Markup186.65-6.0% to today Distribution gives way to Markup after an 11% rise in 3 weeks
2026-10-11Read Distribution168.10+4.3% to today Markup gives way to Distribution first Distribution read since August
2026-10-02Read Markup168.10+4.3% to today ✓Distribution gives way to Markup after a 10% slide in 10 weeks
2026-07-25Read Distribution185.95-5.7% to today ✓Markdown gives way to Distribution

Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.

The full research record, in depth, below
The Label · The Season, Not the Day

This name holds its markup label.

AstraZeneca PLC holds its Markup at $175.41. Consolidating, no directional conviction, held for 10 days.

As held on the ledger · 2026-11-19
PhaseMarkup
Quantitative stateConsolidating, no directional conviction, held for 10 days
Price at the screen$175.41
Valuation27.40 trailing · 28.48 forward price to earnings
Values screenNot scored · score 50.0
Beta0.22
The Workings

Five Screens: AZN's Results

This security has not been fully scored against the values screen yet.

TestFigureLimitStatus
Business activity Permissible Permissible core business Pass
Revenue purity 0.61% Below 5% Pass

Definitions, sources and threshold rules: ticker values-screen methodology.

The Ethical Read

The Read, in Plain English

AstraZeneca clears the business-activity screen and the figures we can measure look clean, but one or more financial figures are still pending, so the verdict is not final yet.

Read as at 2026-11-19. It updates when the underlying figures move, and past reads are kept below.

What the Numbers Say It Is Worth

The Fair Value Range

Our analysis reads Fair vs our fair value, as of 19 Nov 2026: it trades above our 161.69 fair value estimate, moderate competitive moat, 12.50% revenue growth.

Model construction and limits: fair-value methodology.

161.69Conservative161.69Base case185.94Growth case 175.41Price

Fair value range in , drawn from the 2026-11-19 screen. The gold marker is the market price at the same screen. The price runs 8.5% above the base estimate.

The Street's Range
184.00Street low 224.49Street average 245.00Street high 175.41Price

Third-party analyst targets: 10 covering, consensus Strong Buy. The average target sits +28% from the screen price.

Reading the gap · Our more conservative model reads it as fully-to-richly valued here, while the Street is more bullish: a quality-at-a-fair-price name rather than a deep-value one.

Price History & Projections

Where our models see it going: fair-value estimate 161.69 , with a range of 161.69 to 185.94 , dated to the 2026-11-19 screen.

How our estimate and third-party targets differ.

The Business, in Plain Words
The fundamentals · plain-English read
Forward P/E28.5xexpensive even after accounting for its growth
Trailing P/E27.4xa premium valuation
EPS, forward5.90
Revenue growth+12.5%steady growth
Profit margin17.2%healthy profit margins
Return on equity23.5%an exceptional return on shareholder capital
Dividend yield1.76%
Debt to equity0.72moderate, manageable leverage
Current ratio0.91below 1: short-term bills exceed liquid assets
Beta0.22barely tracks the market's swings
Short interest, float0.00%
52-week range136.16 - 212.71
MoatMODERATE
Market cap$260.7B
Employees96,100

AZN-specific watchpoints · The things to watch: its business and earnings are exposed to United Kingdom and to currency swings; as a drug manufacturers - general name, trial and regulatory outcomes can move it sharply either way.

Metric definitions and interpretation rules: ticker-page methodology.

The Dated Journal · Newest First, Never Edited

Every Entry, As Written

2026-11-15 Markup $184.45 -1.1% Entry 19

The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 1.1% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are up 23%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (10 analysts) rates it strong buy, with a mean price target of $224.

2026-11-08 Markup $186.43 -0.1% Entry 18

The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.1% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are up 23%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (10 analysts) rates it strong buy, with a mean price target of $224.

2026-11-01 Markup · changed $186.65 +12.0% Entry 17

The framework has shifted from distribution to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 12.0% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are up 23%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (10 analysts) rates it strong buy, with a mean price target of $224.

2026-10-25 Distribution $166.68 +0.0% Entry 16

The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are up 23%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (10 analysts) rates it strong buy, with a mean price target of $224.

2026-10-18 Distribution $166.68 -0.8% Entry 15

The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.8% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 4% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 23%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (10 analysts) rates it strong buy, with a mean price target of $224.

2026-10-11 Distribution · changed $168.10 +0.0% Entry 14

The framework has shifted from markup to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 4% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 23%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (10 analysts) rates it strong buy, with a mean price target of $224.

2026-10-02 Markup · changed $168.10 -9.6% Entry 13

The framework has shifted from distribution to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 9.6% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 4% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 23%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (10 analysts) rates it strong buy, with a mean price target of $224.

2026-08-27 Distribution $185.95 +0.0% Entry 12

Our analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is holding around 4% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 23%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (10 analysts) rates it strong buy, with a mean price target of $224.

2026-07-27 Distribution $185.95 +0.0% Entry 11

Our analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with ethical pass with moderate score. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 4% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 23%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (10 analysts) rates it strong buy, with a mean price target of $224. It reported earnings in this window, a natural checkpoint for the thesis.

2026-07-26 Distribution $185.95 +0.0% Entry 10

Our analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with ethical pass with moderate score. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 4% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 23%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (10 analysts) rates it strong buy, with a mean price target of $224. It reported earnings in this window, a natural checkpoint for the thesis.

Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.

The Insider Ledger · Form 4 Filings, As Filed
Most recent filings · AZN
DateInsiderTitleTypeSharesValue
2026-05-14 Soriot (Pascal) 18,359 ·
2026-03-05 Soriot (Pascal) 101,495 ·
2026-03-04 Soriot (Pascal) 14,967 ·
2026-03-04 Sarin (Aradhana M.D.) 4,863 ·
2026-01-31 Investor AB · ·
2026-01-31 BlackRock Financial Management, Inc. · ·
2026-01-31 The Capital Group Companies, Inc. · ·
2026-01-31 Wellington Management Company, L.L.P. · ·
2025-12-31 Wallenberg (Marcus) · ·
2025-12-31 Wellington Management Company, L.L.P. · ·

Public filings, recorded as found. The full tape lives at Insider Intelligence.

What Holding Actually Paid · Price Plus Dividends
If $1,000 had been placed · historical, not a promise
PeriodPrice thenPrice returnDivs per share$1,000 becameTotal return
1 month $181.86 -2.0% · $980 -2.0%
2 months $204.03 -12.6% · $874 -12.6%
3 months $192.50 -7.4% · $926 -7.4%
6 months $178.72 -0.3% $2.15 $1,010 +1.0%
1 year $145.13 +22.8% $3.18 $1,250 +25.0%
2 years $154.50 +15.4% $6.28 $1,195 +19.5%
3 years $139.58 +27.7% $9.18 $1,343 +34.3%
5 years $105.80 +68.5% $14.95 $1,826 +82.6%

Historical returns from market close data. Past performance does not guarantee future results.

The Ledger's Promise

This entry now belongs to the ledger. Whatever AZN does next, these words stay.

AstraZeneca PLC · AZN · Markup · $175.41
Recorded 2026-11-19 · before the outcome · scored mechanically

Membership

Thirteen thousand names carry this page. One desk keeps them honest.

Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.

Join the desk

Screening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.

Get our weekly market brief free.